BSG and prostate carcinoma: Previous researches have confirmed the Rap1 signaling is activated in various malignancies, including prostate cancer [38], breast cancer [39], ovarian cancer [40], colon cancer [41], NSCLC [42], etc. In this study, silencing of CD147 led to the blocking of the Rap1 signaling pathway in LUAD cells, evidenced by the down-regulation of Rap1 and p-p38 MAPK/p38 MAPK.